Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > FY2019 H1 Earnings
FY2019 H1 Earnings
-
8 Japan Majors Log Combined Sales Rise in 1st Half on Shire Buy, Solid Earnings at Home
November 6, 2019
-
Bullish New Drugs Mitigated Vesicare/Tarceva Patent Cliff: Astellas CEO
November 1, 2019
-
Daiichi Sankyo Ramps Up R&D Investment for ADC, 16 Studies Added to DS-8201
November 1, 2019
-
Takeda’s Underlying Revenue Skids 0.2% in 1st Half as Rare Disease Biz Weighs
November 1, 2019
-
Despite a Hold by Key Panel, Ono Sees Cachexia Drug Launch in April-September 2020
November 1, 2019
-
Xtandi Helps Astellas Counter Vesicare/Tarceva LOEs in April-September
November 1, 2019
-
Edoxaban Drives Daiichi Sankyo’s Half-Year Earnings
November 1, 2019
-
Ono Checks In 3.2% Revenue Growth on Opdivo, Forxiga in 1st Half
November 1, 2019
-
Shionogi’s Half-Year Sales Slip 4.4% after Xofluza Milestone Gain
October 31, 2019
-
Mitsubishi Tanabe to Give Another Try for Radicava’s EU OK, but in Oral Form: Chief
October 31, 2019
-
Mitsubishi Tanabe Suffers 10% Sales Slide in 1st Half on Gilenya Royalty Row
October 31, 2019
-
Eisai Sees Brisk Sales of Global Brands, but Earnings Slump on One-Off Factors
October 31, 2019
-
Eisai CEO Says Aducanumab Resurrection Was a Surprise, Touts Totality of Data as He Relays New Findings
October 31, 2019
-
Taisho’s Prescription Drug Sales Suffer Double-Digit Decline in H1, due to Capital Tie-Up Dissolution with Toyama Chemical
October 31, 2019
-
To Weather Latuda Cliff, Sumitomo Dainippon Looks to Cash In on Roivant Alliance to Push Priority R&D
October 29, 2019
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…